We’re looking for a Research Software Engineer to join the University of Manchester Research IT Team @UoM_eResearch and work with a friendly team of epidemiological researchers on exciting web development www.bsrbr.org. Full details HERE; apply soon as the closing date is 14th Jan 2019.
What’s in a name?
Recording therapy changes at Clinical Follow Up
With many biosimilars on the market we would like to remind you of the importance of using the drug trade names when completing clinical follow up. Without the trade name it makes it difficult for us to get a full picture of the patient’s treatment history, including knowing which drug they were on at the time of any adverse event.
Dates of changes are also important, please let us know the date of the last dose of the previous drug as well as the new start date. We understand this can be difficult if the patient is starting a new prescription via home delivery or has an old prescription that needs to be used first, but even a month and year can be useful to us rather than a missing date.
If you really can’t get you hands on the information please let us know by making a note on the form so that we do not repeatedly contact you for missing information.
We really appreciate all the details that you provide us with, thank you.
Find all the information you need for recruiting participants with the BSRBR-RA on our registration page.
Whether your patient is new to the register or already participating. There are guides to what drugs we are currently recruiting for, along with all the forms and documents you will need, for new or re-registrations.
If you still have questions about eligibility and recruitment please contact us.
Wondering where all that data we collect goes? Have a look at the newest publications using BSRBR-RA data:
Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register
There are also lay summaries available for many of our publications which provide a more accessible overview. Lay summaries and details of BSRBR-RA publications can be found on our research page.
As usual members of the BSRBR-RA team will be at the conference to present our research and keep you up to date with all the goings on of the BSRBR-RA.
Where to catch us…
Presentations – Tues 1st May
13.15 – 14.15: Latest project news from the BSR Biologics Registers
14.15 – 15-45: BSR Biologics Registers: a scientific update
Posters – Exhibition hall
Tue 1st May, no. 87
Refractory disease in rheumatoid arthritis: results from the British Society of Rheumatology Biologics Register for rheumatoid arthritis. This poster will also be part of the Editor’s picks poster tour, Tues 1st May, 10.30-11.30
Thurs 3rd May, no. 243.
Long-term risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society of Rheumatology Biologics Register for rheumatoid arthritis.
Thurs 3rd May, no. 241.
Profiling rheumatoid arthritis biosimilar switchers: data from the British Society of Rheumatology Biologics Register for rheumatoid arthritis.
Biologics Registers Stand
Come along and say hello to members of our team at our stand. We will have lots of information updates and our team are also eager to answer any questions you have about the register!
Annual statements will be arriving soon; these will update how your centre is doing in terms of recruitment and follow up. Please remember to update us with contact details and get in touch with any queries you have about your statement.
Now is also a good time to make sure those involved with the collecting of data at your centre are included on our contributors list. This is a list of ALL rheumatologists/ nurses/ allied health professionals who have EVER contributed clinical date to the BSRBR-RA since it began in 2001.
There will be a form included with your statement or you can access this via the website and view the current list HERE.
You can now register patients with RA starting, or switching to, a number of new products including Olumiant (baricitinib), Kevzara (sarilumab), Rixathon (rituximab), Erelzi (etanercept) and Xeljanz (tofacitinib).
Updated eligibility table, checklist, re-registration guide and recruitment posters are in the process of being sent out to centres, so keep an eye out for this information in the post. Alongside this documents are being circulated electronically (where possible) and of course being made available on our WEBSITE.
Full details of relevant approvals for these new drugs have previously been circulated and can also be found HERE.
If you can’t find the answer to your questions about recruitment on our website please contact the office and we will do our best to help you.